View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2017	Mar. 05, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	Semler Scientific, Inc.
Entity Central Index Key	0001554859
Trading Symbol	smlr
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		5,939,116
Entity Public Float			$ 9,715,218.00
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current Assets:
Cash	$ 1,457	$ 622
Trade accounts receivable, net of allowance for doubtful accounts of $35 and $87 respectively	1,315	877
Prepaid expenses and other current assets	111	93
Total current assets	2,883	1,592
Assets for lease, net	1,147	875
Property and equipment, net	193	590
Long-term deposits	15	15
Total assets	4,238	3,072
Current liabilities:
Accounts payable	488	450
Accrued expenses	2,670	2,185
Deferred revenue	531	513
Accrued interest, current portion	196
Loans payable, current portion net of debt discount of $9 and $0, respectively	1,018	81
Related party loan payable, current portion net of debt discount of $13 and $0, respectively	237
Total current liabilities	5,140	3,229
Long-term liabilities:
Deferred rent	13	35
Accrued interest		71
Accrued interest - related parties		124
Loans payable net of debt discount of $0 and $65, respectively	26	938
Related party loan payable net of debt discount of $0 and $156, respectively	1,642	1,594
Total long-term liabilities	1,681	2,762
Stockholders' deficit:
Common stock, $0.001 par value; 50,000,000 shares authorized; 5,902,244, and 5,148,568 shares issued, and 5,877,244 and 5,123,568 shares outstanding (treasury shares of 25,000 and 25,000, respectively)	6	5
Additional paid-in capital	23,843	21,998
Accumulated deficit	(26,432)	(24,922)
Total stockholders' deficit	(2,583)	(2,919)
Total liabilities and stockholders' deficit	$ 4,238	$ 3,072

Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance for doubtful accounts on trade accounts receivable (in dollars)	$ 35	$ 87
Debt discount on current portion of Loans payable	9	0
Debt discount on current portion of Related party loan payable	13	0
Debt discount on Loans payable	0	65
Debt discount on Related party loan payable	$ 0	$ 156
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	5,902,244	5,148,568
Common stock, shares outstanding	5,877,244	5,123,568
Treasury stock, shares	25,000	25,000

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
Statements of Operations - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Revenues	$ 12,452	$ 7,434
Operating expenses:
Cost of revenues	2,553	1,873
Engineering and product development	1,831	866
Sales and marketing	5,078	3,827
General and administrative	3,843	3,027
Total operating expenses	13,305	9,593
Loss from operations	(853)	(2,159)
Interest expense	(231)	(124)
Related party interest expense	(233)	(267)
Loss on extinguishment of loans	(179)
Other expense	(14)	(4)
Other expense	(657)	(395)
Net loss	$ (1,510)	$ (2,554)
Net loss per share, basic and diluted (in dollars per share)	$ (0.28)	$ (0.50)
Weighted average number of shares used in computing basic and diluted loss per share (in shares)	5,405,388	5,123,568

Statements of Stockholders' Deficit - USD ($) $ in Thousands	Common Stock	Treasury Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2015	$ 5		$ 21,291	$ (22,368)	$ (1,072)
Balance (in shares) at Dec. 31, 2015	5,148,568	(25,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Warrant Fair Values			407		407
Stock-based Compensation			300		300
Net loss				(2,554)	(2,554)
Balance at Dec. 31, 2016	$ 5		21,998	(24,922)	(2,919)
Balance (in shares) at Dec. 31, 2016	5,148,568	(25,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Private Placement			475		475
Private Placement (in shares)	190,000
Warrant Fair Values			289		289
Warrant Exercises	$ 1		632		633
Warrant Exercises (in shares)	358,676
Stock-based Compensation			343		343
Stock Option Exercise			106		$ 106
Stock Option Exercise (in shares)	205,000				205,000
Net loss				(1,510)	$ (1,510)
Balance at Dec. 31, 2017	$ 6		$ 23,843	$ (26,432)	$ (2,583)
Balance (in shares) at Dec. 31, 2017	5,902,244	(25,000)

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
Statements of Cash Flows - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (1,510)	$ (2,554)
Reconciliation of Net Loss to Net Cash Provided by (Used in) Operating Activities:
Amortization of debt discount	156	185
Accretion of non-cash interest	174
Loss on extinguishment of debt	179
Depreciation	559	452
Loss on impairment of fixed assets	251
Loss on disposal of assets for lease	247	223
Allowance for doubtful accounts	41	108
Stock-based compensation expense	343	300
Changes in Operating Assets and Liabilities:
Trade accounts receivable	(479)	293
Prepaid expenses and other current assets	(18)	(38)
Accounts payable	38	(389)
Accrued expenses	624	55
Deferred revenue	16	(439)
Net Cash Provided by (Used in) Operating Activities	621	(1,804)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment	(47)	(223)
Proceeds from sale of property and equipment	3
Purchase of assets for lease	(924)	(591)
Net Cash Used in Investing Activities	(968)	(814)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	475
Proceeds from exercise of warrants	633
Proceeds from exercise of stock options	106
Proceeds from loans payable	112	2,878
Payments of loans payable	(144)	(43)
Net Cash Provided by Financing Activities	1,182	2,835
INCREASE IN CASH	835	217
CASH, BEGINNING OF PERIOD	622	405
CASH, END OF PERIOD	1,457	622
Cash paid for interest	13	8
Supplemental disclosure of noncash financing activity:
Reclassification of accrued interest to debt upon extinguishment	162
Fair value of warrants issued to lenders	$ 289	$ 407

The Company	12 Months Ended
The Company	Dec. 31, 2017
Company [Abstract]
The Company	1. The Company Semler Scientific, Inc. (the “Company”) was incorporated in the State of Oregon on August 9, 2007, established C-corporation status in 2012, and reincorporated as a Delaware corporation during 2013. The Company is an emerging growth company providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. In 2011, the Company began commercializing its first patented and U.S. Food and Drug Administration (“FDA”) cleared product, which measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease (“PAD”). In March 2015, the Company received FDA 510(k) clearance for the next generation version of its product, QuantaFlo™, which the Company commercially launched in August 2015. The Company has one operating segment and generates revenues domestically primarily through direct licensing to direct customers. The Company is based in San Jose, California.

Going Concern	12 Months Ended
Going Concern	Dec. 31, 2017
Going Concern [Abstract]
Going Concern	2. Going Concern From inception through the third quarter of 2017, the Company incurred recurring losses as a result of costs and expenses related to the Company’s marketing and other promotional activities, and continued research and development of its products. As of December 31, 2017, the Company has negative working capital of $2,257, cash of $1,457 and stockholders’ deficit of $2,583. The Company’s principal sources of cash have included the issuance of equity securities, to a lesser extent, borrowings under loan agreements and revenues from leasing its product. To increase revenues, the Company’s operating expenses will continue to grow and, as a result, the Company will need to generate significant additional revenues to maintain profitability. The Company’s financial statements as of December 31, 2017 have been prepared under the assumption that the Company will continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to attain further operating efficiencies and, ultimately, to generate additional revenues. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company can give no assurances that additional capital that the Company is able to obtain, if any, will be sufficient to meet the Company’s needs. The foregoing conditions raise substantial doubt about the Company’s ability to continue as a going concern.

Summary of Significant Accounting Policies and Estimates

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies and Estimates

Basis for Presentation

The Company’s financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Use of Estimates

The preparation of the accompanying financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses, and related disclosures during the reporting period. Significant items subject to such estimates include revenue recognition, allowance for doubtful accounts, valuation of equipment on lease, deferred tax asset valuation allowance, stock-based compensation and valuation of warrants. These estimates and assumptions are based on management’s best estimates and judgment. Management regularly evaluates its estimates and assumptions using historical experience and other factors; however, actual results could differ significantly from these estimates.

Revenue Recognition

The Company generates revenues primarily from the rental or license of its vascular testing product, or providing diagnostic testing service to its customers. The Company recognizes revenues from the licensing of its vascular testing product pursuant to agreements that automatically renew each month with revenue recognized on a daily convention basis. The Company’s arrangements with customers for its vascular testing product are normally on a month-to-month basis with fees billed at the rates established in the customer agreement. The Company recognizes revenues for providing diagnostic testing services on a per test basis to customers, as earned. The Company also recognizes revenue for hardware and supplies sales as of the date of shipment.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are recorded at the invoiced amount, net of allowances for doubtful accounts. The allowance for doubtful accounts is based on management’s assessment of the collectability of accounts. The Company regularly reviews the adequacy of this allowance for doubtful accounts by considering historical experience, the age of the accounts receivable balances, the credit quality of the customers, current economic conditions, and other factors that may affect customers’ ability to pay to determine whether a specific allowance is appropriate. Accounts receivable deemed uncollectable are charged against the allowance for doubtful accounts when identified.

Assets for Lease

Assets for lease are recorded at cost. At December 31, 2017 and 2016, assets for lease consisted of vascular testing devices, which are leased to customers. The cost of such assets for lease is depreciated on a straight-line basis over 36 months for the units outstanding and recorded as cost of revenues.

The Company regularly reviews whether facts and circumstances exist which indicate that the carrying amounts of assets, may not be recoverable or that the useful life of assets are shorter or longer than originally estimated. The Company assesses the recoverability of its assets by comparing the projected undiscounted net cash flows associated with the related assets over their estimated remaining lives against their respective carrying amounts. The Company considers factors such as estimated usage and expected lives of its assets for lease in this analysis. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. At December 31, 2017 and 2016, there were no impairment indicators.

Property and Equipment

Capital assets are recorded at cost. The cost of such capital assets is depreciated on a straight-line basis over a term depending on the assigned category (described below) and recorded as cost of revenues for WellChec™ capital assets and depreciation for all other capital assets recorded in engineering and product development, sales and marketing and general and administrative expenses.

At December 31, 2017 and 2016, capital assets are classified into one of the following categories:

Category Name			Description
Machinery & Equipment			Manufacturing, R&D, or other non-office equipment
Computer Equipment & Software			Software, computers, monitors, printers and other related equipment.
Furniture & Fixtures			Office equipment and furniture owned by the company

At December 31, 2017 and 2016, capital assets are depreciated based on the following estimated useful life for each category:

Account Name			Useful Life
Machinery & Equipment			Five years
Computer Equipment & Software			Three years
Furniture & Fixtures			Five years

The Company regularly reviews whether facts and circumstances exist which indicate that the carrying amounts of capital assets, may not be recoverable or that the useful life of assets are shorter or longer than originally estimated. The Company assesses the recoverability of its assets by comparing the projected fair value of the related asset over the estimated remaining life against the respective carrying amounts. The Company considers factors such as estimated usage and expected lives of its capital assets in this analysis. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. At December 31, 2017, there was an impairment of the fixed assets used in the WellChec™ business, and, as a result, the Company recorded an impairment of $251 of WellChec™ equipment to general and administrative expense. There was no such impairment in 2016.

Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of the fair value hierarchy under Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, are described as follows:

Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2 — Inputs other than quoted prices included in Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data; and

Level 3 — Unobservable inputs that are supported by little or no market activity, which requires the Company to develop its own models.

The financial instruments of the Company consist primarily of cash, accounts receivable, accounts payable, and loans payable. The carrying amounts of these items are considered a reasonable estimate of fair value at December 31, 2017 and 2016 due to their short-term nature and their market interest rates.

Deferred Revenue

Deferred revenue represents amounts billed to or collected from customers for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The full amount is expected to be recognized as revenues within one year from the balance sheet date and, therefore, such deferred amounts have been classified as current liabilities in the balance sheets presented. The Company generally invoices its clients in advance of a rental period with payment due upon receipt of the invoice.

Debt Discounts

In 2016, the Company secured promissory notes from various accredited investors. These accredited investors were given the opportunity to purchase fully vested warrants exercisable for common stock, which were determined to have a fair value of $407 at issuance which was recorded as debt discount. These debt discounts are being amortized to interest expense over the two-year life of the loan. The Company recognized $156 and $185 of interest expense associated with these discounts in 2017 and 2016, respectively. See Note 8.

Research and Development

The Company expenses costs related to the research and development associated with the design, development, testing and enhancement of its products and services. Such expenses include salaries and related employee benefits, and fees paid to external service providers.

Stock-Based Compensation

Stock-based compensation expense is measured based on the grant-date fair value of the stock-based awards. The Company recognizes stock-based compensation expense for the portion of each option grant or stock award that is expected to vest over the estimated period of service and vesting. The Company uses the Black-Scholes option pricing model as the method for determining the estimated grant-date fair value of stock options. The Black-Scholes option pricing model requires the use of subjective assumptions which determine the fair value of stock-based awards, including the option’s expected volatility. Through 2016, the Company also estimated the forfeiture rate of such awards during the requisite service period. In 2017, upon the adoption of ASU 2016-09, the Company records the forfeitures as they occur. Stock-based compensation expense is recognized on a straight-line basis over the requisite service period of the grant.

Employee Benefit Plan

The Company has a savings plan that qualifies under Section 401(k) of the Internal Revenue Code of 1986, as amended (the “Code”). There were no matching or discretionary employer contributions made to this plan during the years ended December 31, 2017 and 2016.

Income Taxes

The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are recognized for the expected tax consequences attributable to the differences between financial reporting and the tax bases of existing assets and liabilities and net operating loss (“NOL”) carry forwards, and they are measured using enacted tax rates expected to be in effect when differences are expected to reverse. The U.S. Tax Cuts & Jobs Act of 2017 reduced the U.S. corporate income tax rate to 21%, effective January 1, 2018. In addition, NOLs generated after December 31, 2017 are carried forward indefinitely with yearly NOL utilization limited to 80% of taxable income. A valuation allowance is recorded for loss carry-forwards and other deferred tax assets where it is more likely than not that such loss carry-forward and deferred tax assets will not be realized. The estimate for the valuation allowance for deferred tax assets requires management to make significant estimates and judgments about projected future operating results. If actual results differ from these projections or if management’s expectations of future results change, it may be necessary to adjust the valuation allowance. Pursuant to the Securities and Exchange Commission Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), given the amount and complexity of the changes in tax law resulting from the tax legislation, the Company has not finalized the accounting for the income tax effects of the tax legislation. This includes the provisional amounts recorded related to the re-measurement of the deferred taxes and the change to its valuation allowance. The impact of the tax legislation may differ from this estimate, during the one-year measurement period due to, among other things, further refinement of the Company’s calculation, changes in interpretations and assumptions the Company has made, guidance that may be issued and actions the Company may take as a result of the tax legislation.

Net Loss per Share

Basic and diluted net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the periods. For the periods presented, the Company’s outstanding common stock equivalents consisted of options and warrants to purchase shares of common stock, all of which are antidilutive, and therefore were not included in the calculation for diluted loss per share.

Recently Issued Accounting Pronouncements

Accounting Pronouncements Recently Adopted

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This ASU provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a Company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about the company’s ability to continue as a going concern within one year from the date the financial statements are issued. This standard is effective for annual periods ending after December 15, 2016, and for interim periods within annual periods beginning after December 15, 2016 with early adoption permitted. The Company adopted the new standard in the first quarter of fiscal year 2017. The adoption of this standard did not have a material impact on its financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU No. 2016-09”). This ASU simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This standard is effective for the Company’s annual periods beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted the new standard in fiscal year 2017. The adoption of this standard did not have a material impact on its financial statements.

Accounting Pronouncements Not Yet Adopted

In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers. The amendment in this ASU provides guidance on the revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The core principle of this update provides guidance to identify the performance obligations under the contract(s) with a customer and how to allocate the transaction price to the performance obligations in the contract. It further provides guidance to recognize revenue when (or as) the entity satisfies a performance obligation. This standard will replace most existing revenue recognition guidance. On August 8, 2015, the FASB issued ASU 2015-14, which defers the effective date of ASU No. 2014-09 by one year, and permits early adoption as long as the adoption date is not before the original public entity effective date. This standard is effective for the Company’s year ending December 31, 2019 with early adoption permitted for the year ended December 31, 2017. Since the issuance of ASU 2014-09, the FASB has issued several amendments which clarify certain points, including ASU 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU 2016-10, Identifying Performance Obligations and Licensing, ASU 2016-11, Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting, and ASU 2016-12, Narrow-Scope Improvements and Practical Expedients, and ASU No. 2016-20, Technical Corrections and Improvements to Topic 606. The updated revenue standard allows two methods of adoption: (1) retrospectively to each prior period presented (“full retrospective method”), or (2) retrospectively with the cumulative effect recognized in retained earnings as of the date of adoption (“modified retrospective method”). The Company will adopt the new standard using the modified retrospective method in the first quarter of fiscal year 2019. The Company is currently evaluating the effect the new standard will have on its financial statements. The new standard will impact how the Company recognizes revenue under its various contracts and in some cases may accelerate revenue recognition on certain elements on the contract while delaying revenue recognition on other elements and/or deliverables in the contract.

In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes (“ASU 2015-17”), to reduce complexity and simplify the reporting of deferred income tax liabilities and assets. The amendments in this update require that all deferred tax liabilities and assets be classified as noncurrent in a classified balance sheet. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendment of this Update. This standard is effective for the Company’s annual periods beginning after December 15, 2017 and interim periods within annual periods beginning after December 15, 2018, with earlier application permitted, and is not expected to have a significant effect on the Company’s financial position other than reclassification of any short-term deferred tax attributes. The Company will adopt the new standard in fiscal year 2018. The Company maintains full valuation allowances on all deferred tax balances, and therefore, the adoption of this standard is not anticipated to have a material impact on its financial statements.

In January 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU No. 2016-02”). Under the new guidance in ASU No. 2016-02, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at the commencement date: 1) A lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and 2) A right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. Under the new guidance, lessor accounting is largely unchanged, however, certain targeted improvements were made. ASU No. 2016-02 also simplifies the accounting for sale and leaseback transactions. Lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Lessees and lessors may not apply a full retrospective transition approach. The new standard also requires expanded disclosures regarding leasing arrangements. This standard is effective for the Company’s annual periods beginning after December 15, 2019, including interim periods within those fiscal years. The Company will adopt the new standard in the first quarter of fiscal year 2020. The Company generally does not lease equipment or other capital assets, but does lease some of its facilities. The Company is currently evaluating the impact that this new standard will have on its financial statements.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). This ASU requires timelier recording of credit losses on loans and other financial instruments held. Instead of reserves based on a current probability analysis, ASU 2016-13 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. All organizations will now use forward-looking information to better inform their credit loss estimates. ASU 2016-13 requires enhanced disclosures regarding significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization’s portfolio. These disclosures include qualitative and quantitative requirements that provide information about the amounts recorded in the financial statements. In addition, ASU 2016-13 amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. This standard is effective for the Company’s fiscal years beginning after December 15, 2020. The Company will adopt the new standard in fiscal year 2021. The Company is currently evaluating the effect the new standard will have on its financial statements.

Assets for Lease, net

12 Months Ended

Dec. 31, 2017

Leases, Capital [Abstract]

Assets for Lease, net

4. Assets for Lease, net

Assets for lease consist of the following:

	As of December 31,
	2017			2016
Assets for lease		$	1,847		$	1,361
Less: accumulated depreciation			(700)			(486)
Assets for lease, net		$	1,147		$	875

Depreciation expense amounted to $367 and $323 for the years ended December 31, 2017 and 2016, respectively. Reduction to accumulated depreciation for returned items was $152 and $287 for the years ended December 31, 2017 and December 31, 2016, respectively. The Company recognized a loss on disposal of assets for lease in the amount of $247 and $223 for the years ended December 31, 2017 and 2016, respectively.

Property and Equipment, net

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Property and Equipment, net

5. Property and Equipment, net

Capital assets consist of the following:

	As of December 31,
	2017			2016
Capital assets		$	322		$	760
Less: accumulated depreciation			(129)			(170)
Capital assets, net		$	193		$	590

Depreciation expense amounted to $192 and $133 for the years ended December 31, 2017 and 2016, respectively. In addition to depreciation expense, the Company recorded an impairment on fixed assets purchased for its WellChec™ business of $251 for the year ended December 31, 2017. Associated with this impairment to operating expenses, which was recorded to general and administrative expense, there was a reduction to accumulated depreciation of $233 and a reduction to capital assets of $484 for the year ended December 31, 2017. There was no impairment recorded for the year ended December 31, 2016.

Accrued Expenses

12 Months Ended

Dec. 31, 2017

Accrued Liabilities, Current [Abstract]

Accrued Expenses

6. Accrued Expenses

Accrued expenses consist of the following:

	As of December 31,
	2017			2016
Offering Costs		$	0		$	227
Compensation			2,275			1,481
Board of Director Fees			148			182
Miscellaneous Accruals			247			295
Total Accrued Expenses		$	2,670		$	2,185

The accumulated offering costs that were accrued pertain to consulting fees associated with securing equity financing for the Company prior to its initial public offering. Prior to becoming Chief Executive Officer (“CEO”), the Company’s current CEO performed consulting services for the Company, which included managing finance, sales, marketing, operational and strategic planning for the Company, as well as assistance and strategic guidance in securing financing. The Company agreed to further delay and continue to accrue these amounts and increase the balance owed by 1% per month beginning January 1, 2017 to no later than January 31, 2018. All of these offering costs were paid as of December 31, 2017.

Three employees, including the CEO, agreed to further defer amounts accrued to them as of December 31, 2017. The Company agreed to further delay and continue to accrue these amounts and increase the balance owed by 1% per month beginning January 1, 2017 to no later than January 31, 2019.

Two members of the Company’s board of directors have agreed to further defer fees earned from August 2016 to July 2016. The Company agreed to further delay and continue to accrue these amounts and increase the balance owed by 1% per month beginning January 1, 2018 to no later than January 1, 2019.

Concentration of Credit Risk	12 Months Ended
Concentration of Credit Risk	Dec. 31, 2017
Risks and Uncertainties [Abstract]
Concentration of Credit Risk	7. Concentration of Credit Risk Credit risk is the risk of loss from amounts owed by the financial counterparties. Credit risk can occur at multiple levels; as a result of broad economic conditions, challenges within specific sectors of the economy, or from issues affecting individual companies. Financial instruments that potentially subject the Company to credit risk consist of cash and accounts receivable. The Company maintains cash with major financial institutions. The Company’s cash consists of bank deposits held with banks that, at times, exceed federally insured limits. The Company limits its credit risk by dealing with counterparties that are considered to be of high credit quality and by performing periodic evaluations of the relative credit standing of these financial institutions. Concentration of credit risk with respect to accounts receivable is limited due to the large number of customers comprising the payer base. Management periodically monitors the creditworthiness of its customers and believes that it has adequately provided for any exposure to potential credit loss. For the year ended December 31, 2016, one customer accounted for 43.6% of the Company’s revenue. As of December 31, 2016, two customers accounted for 56.0% and 13.7% of the Company’s accounts receivable, respectively. For the year ended December 31, 2017, two customers accounted for 55.0% and 11.1% of the Company’s revenue. As of December 31, 2017, two customers accounted for 56.6% and 23.9% of the Company’s accounts receivable, respectively. As of December 31, 2017 and 2016 the allowance for doubtful accounts was $35 and $87, respectively.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Facilities Leases

The Company recognized facilities lease expenses of $67 and $70 for the years ended December 31, 2017 and 2016, respectively.

On September 23, 2014, the Company entered into a 36-month lease agreement for office space for the sales and marketing team located in Menlo Park, CA. The lease term commenced February 1, 2015 and is effective through January 31, 2018. Payments required under the terms of the lease are $17.0 per month from February 2015 to January 2016, $17.5 per month from February 2016 to January 2017, and $18.0 per month from February 2017 to January 2018. The Company anticipates total future lease payments of $18.0 for the year ended December 31, 2018. On July 15, 2015, the Company entered into a 30-month sublease agreement for the Menlo Park office space, which commenced August 1, 2015 and is effective through the term of the lease, January 31, 2018. Payments required to the Company under the terms of the sublease are $15.5 per month from August 2015 to July 2016, $16.0 per month from August 2016 to July 2017, and $16.5 per month from August 2017 to January 2018. The Company anticipates receipt of total future sublease payments of $16.5 for the year ended December 31, 2018.

Loans Payable

	December 31, 2017						December 31, 2016
Lender	Long-term			Short-term			Long-term			Short-term
Loans from Related Parties
Chang Family Trust		$	1,126					$	1,000
Chang Family Trust			516						500
Glenhill Concentrated Long Master Fund, LLC					$	250			250
Other Loans
Accredited Investor						700			700
Accredited Investor						160			160
Accredited Investor						80			80
Ascentium Capital, LLC						22					$	22
Ascentium Capital, LLC			16			26			42			24
Royal Bank America Leasing, L.P.						28						25
Ascentium Capital, LLC			10			11			21			10
Total			1,668			1,277			2,753			81
Debt Discounts			—			(22)			(221)			—
Total, net of debt discounts		$	1,668		$	1,255		$	2,532		$	81

Loans from Related Parties

On January 15, 2016, the Company entered into a loan agreement with the Chang Family Trust, one of its significant stockholders. Pursuant to the loan agreement, the Company obtained a $1,000 unsecured loan, which initially had a 24-month term, at a fixed interest rate of 10% per annum. Under the loan agreement, the Company will pay $1,000 of principal plus all accrued and unpaid interest at maturity. The Company may prepay the notes at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default, and the Company agreed not to incur additional indebtedness in excess of $50 without the lender’s prior consent, which is not to be unreasonably withheld. In connection therewith, the Company issued the Chang Family Trust a two-year warrant to purchase 114,286 shares of its common stock at an exercise price of $1.75 per share. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

On January 21, 2016, the Company entered into a second loan agreement with the Chang Family Trust. Pursuant to this loan agreement, the Company obtained a $500 unsecured loan, which initially had a 24-month term at a fixed interest rate of 5% per annum. Under this loan agreement, the Company will pay $500 of principal plus all accrued and unpaid interest at maturity. The Company may prepay the notes at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default, and the Company agreed not to incur additional indebtedness in excess of $50 without the lender’s prior consent, which is not to be unreasonably withheld. In connection therewith, the Company issued the Chang Family Trust a two-year warrant to purchase 114,286 shares of its common stock at an exercise price of $1.75 per share. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

On May 2, 2017, the Company entered into an amendment regarding the outstanding promissory notes and warrants issued in January 2016 to the Chang Family Trust. As amended, the maturity date for each note has now been extended by 12 months to January 2019, and the interest rate on the $500 note has been increased to 10.0% per annum for the final 12 months of its term. In each case, interest will accrue on the unpaid principal and accrued interest as of the original two-year maturity date in the final year term of the notes. The other terms of the notes remain unchanged. Additionally, as issued, the warrants were not exercisable, absent receipt of stockholder approval, if after such exercise the holder would be the beneficial owner of more than 19.99% of the Company’s common stock. This condition was removed by the amendments, and accordingly, stockholder approval is no longer required. In connection with the foregoing amendment, the Company issued the Chang Family Trust a warrant to purchase 134,616 shares of its common stock at an exercise price of $2.60 per share. In accordance with FASB ASC 815, these warrants were classified within permanent equity. The warrant expires January 21, 2022, three years after the latest maturity date of the promissory notes, as amended. As part of the amendment, the fair value of the warrants are considered in the calculation when determining whether an amendment resulted in a modification or extinguishment of the original loans and in accordance with FASB ASC 470, the Company recorded the amendment as an extinguishment of the original loans which resulted in a loss on extinguishment of $179 as recorded in the statements of operations.

On November 21, 2016, the Company entered into a loan agreement with Glenhill Concentrated Long Master Fund, LLC, one of its significant stockholders. Pursuant to the loan agreement, the Company obtained a $250 unsecured loan for a 24-month term at a fixed interest rate of 10% per annum. Under the loan agreement, the Company will pay $250 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 28,378 shares of common stock at an exercise price of $1.85 per share. The warrants were not able to be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 9.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan, and the warrants were exercised in full in January 2018.

Other Loans

On March 31, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $700 unsecured loan for a 24-month term at a fixed interest rate of 10% per annum. Under the loan agreement, the Company will pay $700 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 79,459 shares of common stock at an exercise price of $1.85 per share. The warrants were not able to be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan. The warrants were exercised in full in November 2017.

On April 5, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $160 unsecured loan for a 24-month term at a fixed interest rate of 10% per annum. Under the loan agreement, the Company will pay $160 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 18,162 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan, and the warrants were exercised in full in December 2017.

On May 20, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $80 unsecured loan for a 24-month term at a fixed interest rate of 10% per annum. Under the loan agreement, the Company will pay $80 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 9,081 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan, and the warrants were partially exercised in December 2018.

The Company uses the Black-Scholes pricing model to determine the fair market value of warrants. The fair market value of each warrant is estimated on the date of grant. The fair value of warrants issued in conjunction with the related party loans during 2017 was $289. The fair value of all warrants issued in conjunction with the promissory notes during 2016 was $407. The fair value of the warrants granted is estimated on the date of grant using the Black-Scholes pricing model and the following assumptions for the periods presented:

	For the year ended December 31,
	2017		2016
Expected term (in years)		4.75		2
Risk-free interest rate		1.27%		0.73 – 0.89%
Expected volatility		104.6%		97.7 – 99.0%
Expected dividend rate		0%		0%

The assumptions are based on the following for each of the years presented:

Valuation Method — The Company estimates the relative fair value of warrants using the Black-Scholes pricing model.

Expected Term — The Company uses the amount of time the warrants are exercisable per the contractual terms of the award.

Volatility — The Company derives this number from the historical stock volatilities of the Company’s stock over a period approximately equal to the expected term of the warrants.

Risk-free Interest Rate — The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the warrants.

Expected Dividend — The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model.

On July 1, 2016, the Company entered into a software license financing agreement with Ascentium Capital, LLC. Pursuant to the agreement, the Company obtained a $39 loan for a 12-month term at a fixed interest rate of 8.9% per annum. to finance its upfront software licensing fee. The Company had no obligation to make any payments during the first three months, and agreed to pay $4.6 of principal and accrued interest for each of the last 9 months of the term. The loan was able to be prepaid at any time prior to maturity without penalty. The agreement provided for customary events of default. The Company repaid this loan in full at maturity and it is no longer outstanding.

On July 8, 2016, the Company entered into an additional software license financing agreement with Ascentium Capital, LLC. Pursuant to the agreement, the Company obtained a $74 loan for a 36-month term at a fixed interest rate of 8.9% per annum. Under the loan agreement, the Company agreed to make monthly payments of $2.4 of principal and accrued interest. The loan may be prepaid at any time prior to maturity without penalty. The agreement provides for customary events of default. As of the date of this filing, the Company is in compliance with all terms of this loan.

On July 11, 2016, the Company entered into a secured equipment financing agreement with Royal Bank America Leasing, L.P. Pursuant to the agreement, the Company obtained a $140 loan for a 36-month term at a fixed interest rate of 7.3% per annum, which is secured by related equipment. The loan is to be disbursed in three installments. The first installment was for $37. The second installment for $47 was disbursed in July 2017, and the third installment for $56 will be disbursed in July 2018. Under the loan agreement, the Company will pay $3.5 of principal and accrued interest for each of the first 12 months (July 2016 through July 2017), $4.4 of principal and accrued interest for each of months 13-24 (July 2017 through July 2018), and $5.3 of principal and accrued interest for each of months 25-36 (July 2018 through July 2019). The loan may be prepaid at any time only in accordance with the agreement. The agreement provides for customary events of default. As of the date of this filing, the Company is in compliance with all terms of this loan.

On October 2, 2016, the Company entered into a secured equipment financing agreement with Ascentium Capital, LLC. Pursuant to the agreement, the Company obtained a $33 loan for a 36-month term at a fixed interest rate of 9.1% per annum. Under the loan agreement, the Company agreed to make monthly payments of $1.0 of principal and accrued interest. The loan may be prepaid at any time prior to maturity without penalty. The agreement provides for customary events of default. As of the date of this filing, the Company is in compliance with all terms of this loan.

On April 1, 2017, the Company entered into a software license financing agreement with Ascentium Capital, LLC. Pursuant to the agreement, the Company obtained a $63 loan for a 12-month term at a fixed interest rate of 10.3% per annum to finance its upfront software licensing fee. The Company agreed to pay $5.6 of principal and accrued interest for each month of the term. The loan may be prepaid at any time prior to maturity without penalty. The agreement provides for customary events of default. As of the date of this filing, the Company is in compliance with all terms of this loan.

For the years ended December 31, 2017 and 2016, interest expense was $464 and $391 respectively, which included amortization of the debt discount of $156 and $185, respectively.

Indemnification Obligations

The Company enters into agreements with customers, partners, lenders, consultants, lessors, contractors, sales representatives and parties to certain transactions in the ordinary course of the Company’s business. These agreements may require the Company to indemnify the other party against third party claims alleging that its product infringes a patent or copyright. Certain of these agreements require the Company to indemnify the other party against losses arising from: a breach of representations or covenants, claims relating to property damage, personal injury or acts or omissions of the Company, its employees, agents or representatives. The Company has also agreed to indemnify the directors and certain of the officers and employees in accordance with the by-laws of the Company. These indemnification provisions will vary based upon the nature and terms of the agreements. In many cases, these indemnification provisions do not contain limits on the Company’s liability, and the occurrence of contingent events that will trigger payment under these indemnities is difficult to predict. As a result, the Company cannot estimate its potential liability under these indemnities. The Company believes that the likelihood of conditions arising that would trigger these indemnities is remote and, historically, the Company had not made any significant payment under such indemnification provisions. Accordingly, the Company has not recorded any liabilities relating to these agreements. In certain cases, the Company has recourse against third parties with respect to the aforesaid indemnities, and the Company believes it maintains adequate levels of insurance coverage to protect the Company with respect to potential claims arising from such agreements.

Stockholders' Deficit

12 Months Ended

Dec. 31, 2017

Stockholders' Equity Note [Abstract]

Stockholders' Deficit

Stockholders’ Deficit

Authorized Capital

On October 30, 2015, the Company amended and restated its certificate of incorporation and now has 50,000,000 authorized shares of capital stock, all of which are designated as common stock with par value of $0.001 per share.

Common Stock

Issuance of Common Stock

On January 23, 2017, the Company issued and sold 40,000 shares of its common stock to Glenhill Concentrated Long Master Fund, LLC, one of its significant stockholders, pursuant to a stock purchase agreement for $100, which was paid in cash. On February 13, 2017, the Company issued and sold an aggregate of 150,000 shares of its common stock to two accredited investors, including GPG RM Investment, LLC, an affiliate of one of its significant stockholders, pursuant to separate stock purchase agreements for an aggregate purchase price of $375, which was paid in cash.

Voting Rights of Common Stock

Each holder of shares of Common Stock is entitled to one vote for each share held.

Common Stock Warrants

In December 2015, the Company issued an accredited investor two-year warrants to purchase an aggregate of 28,000 shares of common stock at an exercise price of $1.75 per share. The warrants were not able to be exercised, however, absent receipt of stockholder approval, if after such exercise the holder would be the beneficial owner of more than 9.99% of the Company’s common stock. This warrant was exercised in full in December 2017.

In January 2016, the Company issued the Chang Family Trust a two-year warrant to purchase 114,286 shares of common stock at an exercise price of $1.75 per share. The warrants as issued were not exercisable absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 19.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. Also in January 2016, the Company issued the Chang Family Trust a two-year warrant to purchase 114,286 shares of common stock at an exercise price of $1.75 per share. The warrants as issued were not exercisable absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 19.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. The 19.99% limitation was removed by the amendments discussed in Note 8. These warrants were exercised in full in December 2017.

In March 2016, the Company issued an accredited investor a two-year warrant to purchase 79,459 shares of common stock at an exercise price of $1.85 per share. The warrants were not able to be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. This warrant was exercised in full in November 2017.

In April 2016, the Company issued an accredited investor a two-year warrant to purchase 18,162 shares of common stock at an exercise price of $1.85 per share. The warrants were not able to be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. This warrant was exercised in full in December 2017.

In May 2016, the Company issued an accredited investor a two-year warrant to purchase 9,081 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. This warrant was partially exercised in December 2017. There are 6,355 shares that remain available for future exercise.

In November 2016, the Company issued an accredited investor a two-year warrant to purchase an aggregate of 28,378 shares of common stock at an exercise price of $1.85 per share. The warrants were not able to be exercised, however, absent receipt of stockholder approval, if after such exercise the holder would be the beneficial owner of more than 9.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. This warrant was exercised in full in January 2018.

On May 2, 2017, the Company issued the Chang Family Trust a warrant to purchase 134,616 shares of its common stock at an exercise price of $2.60 per share. In accordance with FASB ASC 815, these warrants were classified within permanent equity. The warrant expires January 21, 2022. As part of the loan amendment discussed in Note 8, the fair value of the warrants are considered in the calculation when determining whether an amendment resulted in a modification or extinguishment of the original loans and in accordance with FASB ASC 470, the Company recorded the amendment as an extinguishment of the original loans, which resulted in a loss on extinguishment of $179 as recorded in the statements of operations.

Common Stock

For the years ended December 31, 2017 and 2016, a total of 2,382,444 and 2,800,883 shares of common stock, respectively, were reserved for issuance upon (i) exercise of common stock warrants, and (ii) the exercise of outstanding stock options, as follows:

	Year ended December 31,
	2017		2016
Common stock warrants		527,306		751,366
Options		1,855,138		2,049,517
Total		2,382,444		2,800,883

Stock Option Plan

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Option Plan

10.

Stock Option Plan

The Company’s stock-based compensation program is designed to attract and retain employees while also aligning employees’ interests with the interests of its stockholders. Stock options have been granted to employees under the stockholder-approved 2007 Key Person Stock Option Plan (“2007 Plan”) or the stockholder-approved 2014 Stock Incentive Plan (“2014 Plan”). Stockholder approval of the 2014 Plan became effective in September 2014. The 2014 Plan originally provided that the aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2014 Plan may not exceed 450,000 shares (the “Share Reserve”), however in October 2015, the stockholders approved a 1,500,000 increase to the Share Reserve. In addition, the Share Reserve automatically increases on January 1st of each year, for a period of not more than 10 years, beginning on January 1st of the year following the year in which the 2014 Plan became effective and ending on (and including) January 1, 2024, in an amount equal to 4% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Company’s board of directors may act prior to January 1st of a given year to provide that there will be no January 1st increase in the Share Reserve for such year or that the increase in the Share Reserve for such year will be a lesser number of shares of common stock than would otherwise occur. The Share Reserve is currently 2,548,526 shares for the year ending December 31, 2017.

In light of stockholder approval of the 2014 Plan, the Company no longer grants equity awards under the 2007 Plan. As of December 31, 2017, there were no shares available for future stock-based compensation grants under the 2007 Plan and 880,837 shares of an aggregate total of 2,548,526 shares available for future stock-based compensation grants under the 2014 Plan.

Aggregate intrinsic value represents the difference between the closing market value as of December 31, 2017 of the underlying common stock and the exercise price of outstanding, in-the-money options. A summary of the Company’s stock option activity and related information for 2017 and 2016 is as follows:

	Options Outstanding
	Number of Stock Options Outstanding		Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (In Years)		Aggregate Intrinsic Value (in thousands)
Balance, December 31, 2015		1,909,911		$	2.58		8.56		$	813
Options granted		160,000			2.23
Options forfeited/cancelled		(20,394)			2.23
Balance, December 31, 2016		2,049,517		$	2.58		7.66		$	306
Options granted		180,000			2.10
Options exercised		(205,000)			0.52
Options forfeited/cancelled		(169,379)			3.41
Balance, December 31, 2017		1,855,138		$	2.69		7.48		$	9,850
Exercisable as of December 31, 2016		1,643,417		$	2.60		7.66		$	306
Exercisable as of December 31, 2017		1,465,611		$	2.78		7.27		$	7,646

The total compensation cost related to unvested stock option awards not yet recognized was $633 as of December 31, 2017. The weighted average period over which the total unrecognized compensation cost related to these unvested stock awards will be recognized is 2.2 years. The total number of unvested shares was 389,527 and 406,100 as of December 31, 2017 and 2016, respectively. The total estimated grant date fair value of unvested options was $1,290 and $1,092 as of December 31, 2017 and 2016, respectively. The total estimated grant date fair value of options vested during the years ended December 31, 2017 and 2016 was $343 and $300, respectively. The weighted average grant date fair value of options granted during the year ended December 31, 2017 is $1.61 per share or an aggregate grant date fair value of $290. The weighted average grant date fair value of options granted during the year ended December 31, 2016 is $1.43 per share or an aggregate grant date fair value of $229. The weighted average grant date fair value of options forfeited during the year ended December 31, 2017 was $382. The weighted average grant date fair value of options forfeited during the year ended December 31, 2016 was $30.

In February 2016, the Company’s Compensation Committee granted options to the board of directors, including the CEO, to acquire an aggregate of 160,000 shares under the 2014 plan. Of these, 35,000 options vest annually on the 1-year anniversary of the grant date. The remaining 125,000 shares vest monthly over 48 months such that they are vested in full on the four-year anniversary of the grant date.

In January 2017, the Company’s Compensation Committee granted options to the board of directors, including the CEO, to acquire an aggregate of 140,000 shares under the 2014 plan. Of these, 15,000 options vest annually on the 1-year anniversary of the grant date. The remaining 125,000 shares vest monthly over 48 months such that they are vested in full on the four-year anniversary of the grant date.

In March 2017, the Company’s Compensation Committee granted options to an employee to acquire 30,000 shares under the 2014 plan. The shares vest monthly over 48 months such that they are vested in full on the four-year anniversary of the grant date.

In May 2017, the Company’s Compensation Committee granted options to a consultant to acquire 5,000 shares under the 2014 plan. The shares vest monthly over 12 months such that they are vested in full on the one-year anniversary of the grant date.

In October 2017, the Company’s Compensation Committee granted options to a consultant to acquire 5,000 shares under the 2014 plan. The shares vest monthly over 48 months such that they are vested in full on the four-year anniversary of the grant date.

Determining the Fair Value of Stock Options

The fair value of the options granted is estimated on the date of grant using the Black-Scholes pricing model and the following assumptions for the periods presented:

	Year ended December 31,
	2017		2016
Expected term (in years)		5	5
Risk-free interest rate		1.94 – 2.07%	1.28%
Expected volatility		98.6 – 106.2%	99.9%
Expected dividend rate		0%	0%

The assumptions are based on the following for each of the years presented:

Valuation Method — The Company estimates the fair value of its stock options using the Black-Scholes option pricing model.

Expected Term — The Company estimates the expected term consistent with the simplified method identified by the Securities and Exchange Commission (“SEC”). The Company elected to use the simplified method because of its limited history of stock option exercise activity and its stock options meet the criteria of the “plain-vanilla” options as defined by the SEC. The simplified method calculates the expected term as the average of the vesting and contractual terms of the award.

Volatility — The Company derives this number from the historical stock volatilities of the Company’s stock over a period approximately equal to the expected term of the options.

Risk-free Interest Rate — The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the options.

Forfeiture — For 2016 the Company estimated forfeitures at the time of grant and revised those estimates in subsequent periods if actual forfeitures differed from those estimates. The Company used historical data to estimate pre-vesting forfeitures and recorded stock-based compensation expense only for those awards that were expected to vest. All stock-based payment awards were amortized on a straight-line basis over the requisite service periods of the awards, which were generally the vesting periods. If the Company’s actual forfeiture rate was materially different from its estimate, the stock-based compensation expense could have been significantly different from what the Company recorded in the current period. Following the adoption of ASU 2016-09, the Company no longer estimates forfeitures at the time of grant but records the forfeitures as they occur.

The Company has recorded an expense of $343 and $300 as it relates to stock-based compensation for the years ended December 31, 2017 and 2016, respectively, which was allocated as follows based on the role and responsibility of the recipient in the Company:

	Year ended December 31,
	2017			2016
Cost of Revenues		$	2		$	2
Engineering and Product Development			48			47
Sales and Marketing			93			94
General and Administrative			200			157
Total		$	343		$	300

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes

11. Income Taxes

The components of the provision for income taxes are as follows:

	2017			2016
Current tax provision:
Federal		$	—		$	—
State			15			10
Deferred tax provision:
Federal			—			—
State			—			—
Total		$	15		$	10

These tax expenses are included in other expense in the statements of operations.

A summary of the differences between the Company’s effective income tax rate and the federal statutory income tax rate for the years ended December 31, 2017 and 2016 are as follows:

	2017		2016
Federal statutory rate		21.00%		34.00%
State income tax rate, net of federal benefit		15.00%		(0.2)%
Change in valuation allowance		134.91%		(26.85)%
Change in U.S. Corporate Tax Rate (2017 U.S. Tax Act)		(171.36)%		—
Other		(0.41)%		(7.26)%
Effective income tax rate		(1.15)%		(0.31)%

Deferred tax assets are comprised of the following at December 31:

	2017			2016
Net operating loss carryforwards			4,277			5,730
Deferred revenue			137			194
Depreciation and amortization			23			30
Stock based compensation			635			1,089
Accrual and reserves			291			117
Research and development credits, net of tax reserve			92			96
Total gross deferred tax assets			5,455			7,256
Less valuation allowance			(5,455)			(7,256)
Net deferred tax assets		$	—		$	—

The net change in the valuation allowance for December 31, 2017 was a decrease of $1,801. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company recorded a full valuation allowance on its deferred tax asset balances in the current year.

Federal and California tax laws impose significant restrictions on the utilization of NOL carryforwards in the event of a change in ownership of the Company, as defined by Code Section 382 (“Section 382”). The Company does not believe a change in ownership, as defined by Section 382, has occurred but a formal study has not been completed.

The Company has NOL carryforwards for federal and California income tax purposes of approximately $16,946 and $8,044, respectively, as of December 31, 2017. The federal NOL carryforwards, if not utilized, will expire beginning in 2032. The state NOL carryforwards, if not utilized, will expire beginning in 2031. Under The U.S. Tax Cuts & Jobs Act, passed into law in December 2017 and effective January 1, 2018, NOLs generated after December 31, 2017 will be carried forward indefinitely with the yearly NOL utilization limited to 80% of taxable income.

As of December 31, 2017, and 2016, the Company had no unrecognized tax benefits and no adjustments to liabilities or operations that were required for uncertain tax positions under ASC 740-10. The Company’s practice is to recognize interest and penalty expenses related to uncertain tax positions in income tax expense, which was zero for the years ended December 31, 2017 and 2016. The Company files income tax returns in the U.S. federal and several state tax jurisdictions.

The Company’s tax years beginning in 2013 remain open for examination by the state tax authorities for four years. The Company’s tax years beginning in 2014 remain open for examination by the federal tax authorities for three years. Tax years beginning in 2012 will remain open for examination from the date of utilization of any NOL or credits. The Company does not have any tax positions for which it is reasonably possible the total amount of gross unrecognized tax benefits will increase or decrease within 12 months of the year-ended December 31, 2017.

The U.S. Tax Cuts & Jobs Act reduced the U.S. corporate income tax rate from 34% to 21%. Consequently, the Company recorded a decrease to deferred taxes to the 21% corporate income tax rate of $2,288, which was offset by valuation allowance for the year ended December 31, 2017.

Net loss per share, basic and diluted

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Net loss per share, basic and diluted

12. Net loss per share, basic and diluted

The following table presents the calculation of basic and diluted net loss per share:

	Year ended December 31,
	2017			2016
Net loss		$	(1,510)		$	(2,554)
Weighted average shares outstanding			5,405,388			5,123,568
Basic and diluted loss per share		$	(0.28)		$	(0.50)

Because the Company was in a loss position for each of the periods presented, diluted net loss per share is the same as basic net loss per share for each period as the inclusion of all potential common shares outstanding would have been anti-dilutive. The following weighted average shares outstanding of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been anti-dilutive:

	Year ended December 31,
	2017		2016
Weighted average shares outstanding:
Common stock warrants		747,121		387,599
Options		2,094,903		2,044,902
Total		2,842,024		2,732,501

Summary of Significant Accounting Policies and Estimates (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Basis for Presentation

The Company’s financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Use of Estimates

Revenue Recognition

Accounts Receivable and Allowance for Doubtful Accounts

Assets for Lease

Property and Equipment

At December 31, 2017 and 2016, capital assets are classified into one of the following categories:

Category Name			Description
Machinery & Equipment			Manufacturing, R&D, or other non-office equipment
Computer Equipment & Software			Software, computers, monitors, printers and other related equipment.
Furniture & Fixtures			Office equipment and furniture owned by the company

At December 31, 2017 and 2016, capital assets are depreciated based on the following estimated useful life for each category:

Account Name			Useful Life
Machinery & Equipment			Five years
Computer Equipment & Software			Three years
Furniture & Fixtures			Five years

Fair Value of Financial Instruments

Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 3 — Unobservable inputs that are supported by little or no market activity, which requires the Company to develop its own models.

Deferred Revenue

Debt Discounts

Research and Development

Stock-Based Compensation

Employee Benefit Plan

Income Taxes

Net Loss per Share

Recently Issued Accounting Pronouncements

Accounting Pronouncements Recently Adopted

Accounting Pronouncements Not Yet Adopted

Assets for Lease, net (Tables)

12 Months Ended

Dec. 31, 2017

Leases, Capital [Abstract]

Schedule of assets for lease

	As of December 31,
	2017			2016
Assets for lease		$	1,847		$	1,361
Less: accumulated depreciation			(700)			(486)
Assets for lease, net		$	1,147		$	875

Property and Equipment, net (Tables)

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Schedule of capital assets

	As of December 31,
	2017			2016
Capital assets		$	322		$	760
Less: accumulated depreciation			(129)			(170)
Capital assets, net		$	193		$	590

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2017

Accrued Liabilities, Current [Abstract]

Schedule of accrued expenses

	As of December 31,
	2017			2016
Offering Costs		$	0		$	227
Compensation			2,275			1,481
Board of Director Fees			148			182
Miscellaneous Accruals			247			295
Total Accrued Expenses		$	2,670		$	2,185

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of Loans Payable

	December 31, 2017						December 31, 2016
Lender	Long-term			Short-term			Long-term			Short-term
Loans from Related Parties
Chang Family Trust		$	1,126					$	1,000
Chang Family Trust			516						500
Glenhill Concentrated Long Master Fund, LLC					$	250			250
Other Loans
Accredited Investor						700			700
Accredited Investor						160			160
Accredited Investor						80			80
Ascentium Capital, LLC						22					$	22
Ascentium Capital, LLC			16			26			42			24
Royal Bank America Leasing, L.P.						28						25
Ascentium Capital, LLC			10			11			21			10
Total			1,668			1,277			2,753			81
Debt Discounts			—			(22)			(221)			—
Total, net of debt discounts		$	1,668		$	1,255		$	2,532		$	81

Schedule of relative fair value of the warrants granted using the Black-Scholes pricing model

	For the year ended December 31,
	2017		2016
Expected term (in years)		4.75		2
Risk-free interest rate		1.27%		0.73 – 0.89%
Expected volatility		104.6%		97.7 – 99.0%
Expected dividend rate		0%		0%

Stockholders' Deficit (Tables)

12 Months Ended

Dec. 31, 2017

Stockholders' Equity Note [Abstract]

Schedule of common stock reserved for issuance

	Year ended December 31,
	2017		2016
Common stock warrants		527,306		751,366
Options		1,855,138		2,049,517
Total		2,382,444		2,800,883

Stock Option Plan (Tables)

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of summary of stock-based compensation activity

	Options Outstanding
	Number of Stock Options Outstanding		Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (In Years)		Aggregate Intrinsic Value (in thousands)
Balance, December 31, 2015		1,909,911		$	2.58		8.56		$	813
Options granted		160,000			2.23
Options forfeited/cancelled		(20,394)			2.23
Balance, December 31, 2016		2,049,517		$	2.58		7.66		$	306
Options granted		180,000			2.10
Options exercised		(205,000)			0.52
Options forfeited/cancelled		(169,379)			3.41
Balance, December 31, 2017		1,855,138		$	2.69		7.48		$	9,850
Exercisable as of December 31, 2016		1,643,417		$	2.60		7.66		$	306
Exercisable as of December 31, 2017		1,465,611		$	2.78		7.27		$	7,646

Schedule of weighted-average Black-Scholes fair value assumptions

	Year ended December 31,
	2017		2016
Expected term (in years)		5	5
Risk-free interest rate		1.94 – 2.07%	1.28%
Expected volatility		98.6 – 106.2%	99.9%
Expected dividend rate		0%	0%

Schedule of stock-based compensation based on the role and responsibility of the recipient in the Company

	Year ended December 31,
	2017			2016
Cost of Revenues		$	2		$	2
Engineering and Product Development			48			47
Sales and Marketing			93			94
General and Administrative			200			157
Total		$	343		$	300

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Schedule of components of the provision for income taxes

	2017			2016
Current tax provision:
Federal		$	—		$	—
State			15			10
Deferred tax provision:
Federal			—			—
State			—			—
Total		$	15		$	10

Schedule of differences between the Company's effective income tax rate and the Federal statutory income tax rate

	2017		2016
Federal statutory rate		21.00%		34.00%
State income tax rate, net of federal benefit		15.00%		(0.2)%
Change in valuation allowance		134.91%		(26.85)%
Change in U.S. Corporate Tax Rate (2017 U.S. Tax Act)		(171.36)%		—
Other		(0.41)%		(7.26)%
Effective income tax rate		(1.15)%		(0.31)%

Schedule of deferred tax assets

	2017			2016
Net operating loss carryforwards			4,277			5,730
Deferred revenue			137			194
Depreciation and amortization			23			30
Stock based compensation			635			1,089
Accrual and reserves			291			117
Research and development credits, net of tax reserve			92			96
Total gross deferred tax assets			5,455			7,256
Less valuation allowance			(5,455)			(7,256)
Net deferred tax assets		$	—		$	—

Net loss per share, basic and diluted (Tables)

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Schedule of basic and diluted net loss per share

	Year ended December 31,
	2017			2016
Net loss		$	(1,510)		$	(2,554)
Weighted average shares outstanding			5,405,388			5,123,568
Basic and diluted loss per share		$	(0.28)		$	(0.50)

Schedule of common stock equivalents excluded from the computation of diluted net loss per share

	Year ended December 31,
	2017		2016
Weighted average shares outstanding:
Common stock warrants		747,121		387,599
Options		2,094,903		2,044,902
Total		2,842,024		2,732,501

Going Concern (Detail Textuals) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Going Concern [Abstract]
Working capital surplus (deficit)	$ (2,257)
Cash	1,457	$ 622	$ 405
Stockholders' deficit	$ (2,583)	$ (2,919)	$ (1,072)

Summary of Significant Accounting Policies and Estimates (Detail Textuals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Description of assets for lease	Assets for lease is depreciated on a straight-line basis over 36 months for the units outstanding and recorded as cost of revenues.
Impairment of WellChec equipment	$ 251
Fair value of warrants exercisable for common stock at issuance	407
Amortized interest expense	$ 156	$ 185
Corporate income tax rate effective in 2018	21.00%
Carried forward NOL utilization limit	80%
Machinery & Equipment
Property, Plant and Equipment [Line Items]
Capital assets depreciated assumed useful life	Five years
Computer Equipment & Software
Property, Plant and Equipment [Line Items]
Capital assets depreciated assumed useful life	Three years
Furniture & Fixtures
Property, Plant and Equipment [Line Items]
Capital assets depreciated assumed useful life	Five years

Assets for lease, net - Summary of assets for lease (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Leases, Capital [Abstract]
Assets for lease	$ 1,847	$ 1,361
Less: accumulated depreciation	(700)	(486)
Assets for lease, net	$ 1,147	$ 875

Assets for lease, net (Detail Textuals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Leases, Capital [Abstract]
Depreciation expense	$ 367	$ 323
Accumulated depreciation reduction for returned items	152	287
Loss on disposal of assets for lease	$ (247)	$ (223)

Property and Equipment, net (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Capital assets	$ 322	$ 760
Less: accumulated depreciation	(129)	(170)
Capital assets, net	$ 193	$ 590

Property and Equipment, net (Detail Textuals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 192	$ 133
Impairment on fixed assets purchased	251
Accumulated depreciation reduction	233
Capital assets reduction	$ 484

Accrued Expenses - Summary of accrued expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accrued Liabilities, Current [Abstract]
Offering Costs	$ 0	$ 227
Compensation	2,275	1,481
Board of Director Fees	148	182
Miscellaneous Accruals	247	295
Total Accrued Expenses	$ 2,670	$ 2,185

Accrued Expenses (Detail Textuals)	12 Months Ended
Accrued Expenses (Detail Textuals)	Dec. 31, 2017
Accrued Liabilities, Current [Abstract]
Percentage increase in balance owed	1.00%

Concentration of Credit Risk (Detail Textuals) $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($) Customer	Dec. 31, 2016 USD ($) Customer
Concentration Risk [Line Items]
Allowance for doubtful accounts \| $	$ 35	$ 87
Sales revenue \| Customer concentration risk
Concentration Risk [Line Items]
Number of customers	2	1
Sales revenue \| Customer concentration risk \| Customer one
Concentration Risk [Line Items]
Concentration risk percentage	55.00%	43.60%
Sales revenue \| Customer concentration risk \| Customer two
Concentration Risk [Line Items]
Concentration risk percentage	11.10%
Accounts receivable \| Customer concentration risk
Concentration Risk [Line Items]
Number of customers	2	2
Accounts receivable \| Customer concentration risk \| Customer one
Concentration Risk [Line Items]
Concentration risk percentage	56.60%	56.00%
Accounts receivable \| Customer concentration risk \| Customer two
Concentration Risk [Line Items]
Concentration risk percentage	23.90%	13.70%

Commitments and Contingencies (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Long-term, Total	$ 1,668	$ 2,753
Long-term, Debt Discounts	0	(221)
Long-term, Total, net of debt discounts	1,668	2,532
Short-term, Total	1,277	81
Short-term, Debt Discounts	(22)	0
Short-term, Total, net of debt discounts	1,255	81
Chang Family Trust
Debt Instrument [Line Items]
Long-term, Total	1,126	1,000
Chang Family Trust
Debt Instrument [Line Items]
Long-term, Total	516	500
Glenhill Concentrated Long Master Fund, LLC
Debt Instrument [Line Items]
Long-term, Total		250
Short-term, Total	250
Accredited Investor
Debt Instrument [Line Items]
Long-term, Total		700
Short-term, Total	700
Accredited Investor
Debt Instrument [Line Items]
Long-term, Total		160
Short-term, Total	160
Accredited Investor
Debt Instrument [Line Items]
Long-term, Total		80
Short-term, Total	80
Ascentium Capital, LLC
Debt Instrument [Line Items]
Short-term, Total	22	22
Ascentium Capital, LLC
Debt Instrument [Line Items]
Long-term, Total	16	42
Short-term, Total	26	24
Royal Bank America Leasing, L.P.
Debt Instrument [Line Items]
Short-term, Total	28	25
Ascentium Capital, LLC
Debt Instrument [Line Items]
Long-term, Total	10	21
Short-term, Total	$ 11	$ 10

Commitments and Contingencies (Details 2) - Warrant	12 Months Ended
Commitments and Contingencies (Details 2) - Warrant	Dec. 31, 2017	Dec. 31, 2016
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected term (in years)	4 years 9 months	2 years
Risk-free interest rate	1.27%
Expected volatility	104.60%
Expected dividend rate	0.00%	0.00%
Minimum
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate		0.73%
Expected volatility		97.70%
Maximum
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate		0.89%
Expected volatility		99.00%

Commitments and Contingencies (Detail Textuals) - USD ($)		1 Months Ended	12 Months Ended
	Jul. 15, 2015	Sep. 23, 2014	Dec. 31, 2017	Dec. 31, 2016
Property Subject to or Available for Operating Lease [Line Items]
Facilities lease expense			$ 67,000	$ 70,000
Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Term specified for lease agreement		36 months
Anticipates total future lease payments			18,000
Sub Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Term specified for lease agreement	30 months
Anticipates receipt of total future sublease payments			16,500
Lease term from February 2015 to January 2016 \| Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement			17,000
Lease term from February 2016 to January 2017 \| Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement			17,500
Lease term from February 2017 to January 2018 \| Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement			18,000
Lease term from August 2015 to July 2016 \| Sub Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Sublease payments			15,500
Lease term from August 2016 to July 2017 \| Sub Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Sublease payments			16,000
Lease term from August 2017 to January 2018 \| Sub Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Sublease payments			$ 16,500

Commitments and Contingencies (Detail Textuals 1) - USD ($)								1 Months Ended					12 Months Ended
	May 02, 2017	Oct. 02, 2016	Jul. 11, 2016	Jul. 08, 2016	Jul. 01, 2016	Apr. 05, 2016	Jan. 15, 2016	Apr. 01, 2017	Nov. 21, 2016	May 20, 2016	Mar. 31, 2016	Jan. 21, 2016	Dec. 31, 2017	Dec. 31, 2016
Commitments And Contingencies [Line Items]
Interest expense													$ 464,000	$ 391,000
Amortization of debt discount													156,000	185,000
Fair value of warrants with promissory notes													289,000	$ 407,000
Loss on extinguishment of loans													$ (179,000)
Software License Financing Agreement \| Ascentium Capital, LLC
Commitments And Contingencies [Line Items]
Amount of loan obtained				$ 74,000	$ 39,000			$ 63,000
Term of loan				36 months	12 months			12 months
Annual fixed interest rate				8.90%	8.90%			10.30%
Monthly principal plus accrued interest payment				$ 2,400	$ 4,600			$ 5,600
Term of interest and principal payments					9 months
Secured Equipment Financing Agreement \| Royal Bank America Leasing, L.P.
Commitments And Contingencies [Line Items]
Amount of loan obtained			$ 140,000
Term of loan			36 months
Annual fixed interest rate			7.30%
First installment			$ 37,000
Second installment disbursed in July 2017			47,000
Third installment disbursed in July 2018			56,000
Secured Equipment Financing Agreement \| Royal Bank America Leasing, L.P. \| July 2016 through July 2017
Commitments And Contingencies [Line Items]
Principal and accrued interest payable			3,500
Secured Equipment Financing Agreement \| Royal Bank America Leasing, L.P. \| July 2017 through July 2018
Commitments And Contingencies [Line Items]
Principal and accrued interest payable			4,400
Secured Equipment Financing Agreement \| Royal Bank America Leasing, L.P. \| July 2018 through July 2019
Commitments And Contingencies [Line Items]
Principal and accrued interest payable			$ 5,300
Secured Equipment Financing Agreement \| Ascentium Capital, LLC
Commitments And Contingencies [Line Items]
Amount of loan obtained		$ 33,000
Term of loan		36 months
Annual fixed interest rate		9.10%
Monthly principal plus accrued interest payment		$ 1,000
Unsecured Debt \| Loan Agreement \| Accredited Investor
Commitments And Contingencies [Line Items]
Amount of loan obtained						$ 160,000				$ 80,000	$ 700,000
Term of loan						24 months				24 months	24 months
Annual fixed interest rate						10.00%				10.00%	10.00%
Monthly principal plus accrued interest payment						$ 160,000				$ 80,000	$ 700,000
Warrant term						2 years				2 years	2 years
Number of warrant issued to purchase common stock						18,162				9,081	79,459
Threshold limit of common stock on exceeding which need shareholders approval for exercising						4.99%				4.99%	4.99%
Exercise price per warrants						$ 1.85				$ 1.85	$ 1.85
Unsecured Debt \| Loan Agreement \| Glenhill Concentrated Long Master Fund, LLC
Commitments And Contingencies [Line Items]
Amount of loan obtained									$ 250,000
Term of loan									24 months
Annual fixed interest rate									10.00%
Monthly principal plus accrued interest payment									$ 250,000
Warrant term									2 years
Number of warrant issued to purchase common stock									28,378
Threshold limit of common stock on exceeding which need shareholders approval for exercising									9.99%
Exercise price per warrants									$ 1.85
Unsecured Debt \| Loan Agreement \| Chang Family Trust \| William H C Chang
Commitments And Contingencies [Line Items]
Amount of loan obtained							$ 1,000,000					$ 500,000
Term of loan							24 months					24 months
Annual fixed interest rate							10.00%					5.00%
Monthly principal plus accrued interest payment							$ 1,000,000					$ 500,000
Additional indebtness							$ 50,000					$ 50,000
Warrant term							2 years					2 years
Number of warrant issued to purchase common stock							114,286					114,286
Exercise price per warrants							$ 1.75					$ 1.75
Unsecured Debt \| Amended loan agreement \| Chang Family Trust \| William H C Chang
Commitments And Contingencies [Line Items]
Term of loan	2 years
Warrant term	3 years
Number of warrant issued to purchase common stock	134,616
Exercise price per warrants	$ 2.60
Specific portion of notes on which rate of interest increased	$ 500,000
Rate of interest charged on specific portion of note	10.00%
Extended maturity of promissory notes	12 months
Minimum percentage holding required by holder to retain exercising rights	more than 19.99%
Loss on extinguishment of loans	$ (179,000)

Stockholders' Deficit (Details) - shares	Dec. 31, 2017	Dec. 31, 2016
Stockholders Equity Deficit [Line Items]
Total	2,382,444	2,800,883
Common stock warrants
Stockholders Equity Deficit [Line Items]
Total	527,306	751,366
Options
Stockholders Equity Deficit [Line Items]
Total	1,855,138	2,049,517

Stockholders' Deficit (Detail Textuals) - $ / shares	Dec. 31, 2017	Dec. 31, 2016	Oct. 30, 2015
Stockholders' Equity Note [Abstract]
Common stock, shares authorized	50,000,000	50,000,000	50,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001

Stockholders' Deficit (Detail Textuals 1) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended						12 Months Ended
	May 02, 2017	Apr. 05, 2016	Jan. 15, 2016	Feb. 13, 2017	Jan. 23, 2017	Nov. 21, 2016	May 20, 2016	Mar. 31, 2016	Jan. 21, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Stockholders Equity Deficit [Line Items]
Value of common of common stock issued and sold										$ 475
Stock-based compensation expense										$ 343	$ 300
Number of shares in reserve										2,382,444	2,800,883
Loss on extinguishment of loans										$ (179)
Glenhill Concentrated Long Master Fund, LLC
Stockholders Equity Deficit [Line Items]
Number of common stock issued and sold					40,000
Value of common of common stock issued and sold					$ 100
GPG RM Investment, LLC
Stockholders Equity Deficit [Line Items]
Number of common stock issued and sold				150,000
Value of common of common stock issued and sold				$ 375
Common Stock
Stockholders Equity Deficit [Line Items]
Number of common stock issued and sold										190,000
Unsecured Debt \| Chang Family Trust \| Loan Agreement \| William H C Chang
Stockholders Equity Deficit [Line Items]
Exercise price per warrants			$ 1.75						$ 1.75
Number of warrant issued to purchase common stock			114,286						114,286
Warrant term			2 years						2 years
Unsecured Debt \| Chang Family Trust \| Amended loan agreement \| William H C Chang
Stockholders Equity Deficit [Line Items]
Exercise price per warrants	$ 2.60
Number of warrant issued to purchase common stock	134,616
Warrant term	3 years
Loss on extinguishment of loans	$ (179)
Unsecured Debt \| Accredited investors \| Loan Agreement
Stockholders Equity Deficit [Line Items]
Threshold limit of common stock on exceeding which need shareholders approval for exercising		4.99%					4.99%	4.99%
Exercise price per warrants		$ 1.85					$ 1.85	$ 1.85
Number of warrant issued to purchase common stock		18,162					9,081	79,459
Warrant term		2 years					2 years	2 years
Number of shares in reserve							6,355
Unsecured Debt \| Glenhill Concentrated Long Master Fund, LLC \| Loan Agreement
Stockholders Equity Deficit [Line Items]
Threshold limit of common stock on exceeding which need shareholders approval for exercising						9.99%
Exercise price per warrants						$ 1.85
Number of warrant issued to purchase common stock						28,378
Warrant term						2 years
Private placement
Stockholders Equity Deficit [Line Items]
Threshold limit of common stock on exceeding which need shareholders approval for exercising												9.99%
Exercise price per warrants												$ 1.75
Number of warrant issued to purchase common stock												28,000
Warrant term												2 years

Stock Option Plan - Summary of stock-based compensation activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Number of Stock Options Outstanding
Balance	2,049,517	1,909,911
Granted	180,000	160,000
Exercised	(205,000)
Forfeited/Cancelled	(169,379)	(20,394)
Balance	1,855,138	2,049,517	1,909,911
Exercisable	1,465,611	1,643,417
Weighted Average Exercise Price
Balance	$ 2.58	$ 2.58
Granted	2.10	2.23
Exercised	0.52
Forfeited/Cancelled	3.41	2.23
Balance	2.69	2.58	$ 2.58
Exercisable	$ 2.78	$ 2.60
Weighted Average Remaining Contractual Term, Options Outstanding (in years)	7 years 5 months 23 days	7 years 7 months 28 days	8 years 6 months 22 days
Weighted Average Remaining Contractual Term, Options Exercisable (in years)	7 years 3 months 7 days	7 years 7 months 28 days
Aggregate Intrinsic Value, Options Outstanding	$ 9,850	$ 306	$ 813
Aggregate Intrinsic Value, Options Exercisable	$ 7,646	$ 306

Stock Option Plan - Weighted-average Black-Scholes fair value assumptions (Details 1)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	5 years	5 years
Risk free interest rate		1.28%
Expected volatility		99.90%
Expected dividend yield	0.00%	0.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	2.07%
Expected volatility	106.20%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.94%
Expected volatility	98.60%

Stock Option Plan - Stock-based compensation (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 343	$ 300
Cost of Revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2	2
Engineering and Product Development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	48	47
Sales and Marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	93	94
General and Administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 200	$ 157

Stock Option Plan (Detail Textuals) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Oct. 31, 2015	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares in reserve		2,382,444	2,800,883
Stock-based compensation expense		$ 343	$ 300
Total unrecognized compensation cost related to non-vested awards		$ 633
Weighted average period of unvested stock awards		2 years 2 months 12 days
Total estimated grant date fair value of options non-vested		$ 1,290	1,092
Total estimated grant date fair value of options vested		$ 343	$ 300
Weighted average grant date fair value of options granted		$ 1.61	$ 1.43
Weighted average grant date fair value of options forfeited		$ 382	$ 30
Aggregate grant date fair value		$ 290	$ 229
Total number of unvested shares		389,527	406,100
2014 Stock Incentive Plan ("2014 Plan") \| Employee stock option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares reserve increase		4.00%
Number of shares in reserve		2,548,526
Number of stock options vested		880,837
Aggregate number of shares		450,000
Additional authorized shares	1,500,000
Maximum term of stock option grants		10 years

Stock Option Plan (Detail Textuals 1) - USD ($) $ in Thousands	1 Months Ended						12 Months Ended
	Oct. 31, 2017	May 31, 2017	Mar. 31, 2017	Jan. 31, 2017	Feb. 29, 2016	Oct. 31, 2015	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense							$ 343	$ 300
Number of stock options granted							180,000	160,000
Number of stock option forfeited							169,379	20,394
Number of stock options exercised							205,000
2014 Stock Incentive Plan ("2014 Plan") \| Employee stock option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares							450,000
Additional authorized shares						1,500,000
2014 Stock Incentive Plan ("2014 Plan") \| Employee stock option \| Board of Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options vested and exercisable				15,000	35,000
Number of stock options granted				140,000	160,000
Vesting period of option				48 months	48 months
Number of shares remaining to vest				125,000	125,000
Number of years in options fully vested				4 years	4 years
2014 Stock Incentive Plan ("2014 Plan") \| Employee stock option \| Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options granted			30,000
Vesting period of option			48 months
Number of years in options fully vested			4 years
2014 Stock Incentive Plan ("2014 Plan") \| Employee stock option \| Consultant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options granted	5,000	5,000
Vesting period of option	48 months	12 months
Number of years in options fully vested	4 years	1 year

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current tax provision:
Federal	$ 0	$ 0
State	15	10
Deferred tax provision:
Federal	0	0
State	0	0
Total	$ 15	$ 10

Income Taxes (Details 1)	12 Months Ended
Income Taxes (Details 1)	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Federal statutory rate	21.00%	34.00%
State income tax rate, net of federal benefit	15.00%	(0.20%)
Change in valuation allowance	134.91%	(26.85%)
Change in U.S. Corporate Tax Rate (2017 U.S. Tax Act)	(171.36%)
Other	(0.41%)	(7.26%)
Effective income tax rate	(1.15%)	(0.31%)

Income Taxes (Details 2) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Net operating loss carryforwards	$ 4,277	$ 5,730
Deferred revenue	137	194
Depreciation and amortization	23	30
Stock-based compensation	635	1,089
Accrual and reserves	291	117
Research and development credits, net of tax reserve	92	96
Total gross deferred tax assets	5,455	7,256
Less valuation allowance	(5,455)	(7,256)
Net deferred tax assets	$ 0	$ 0

Income Taxes (Detail Textuals) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Detail Textuals) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Tax Credit Carryforward [Line Items]
Net operating loss carryforwards for federal	$ 16,946
Net operating loss carryforwards for California	8,044
Net change in the valuation allowance	$ 1,801
Effective taxable rate	80%
Corporate income tax rate	21.00%
Federal statutory rate	21.00%	34.00%
Deferred taxes of valuation allowance	$ 2,288	$ 0
Federal
Tax Credit Carryforward [Line Items]
Income penalties expense	$ 0
Operating Loss Carryforwards Expiration Period	2032
Company's tax years beginning for examination	3 years
State
Tax Credit Carryforward [Line Items]
Income penalties expense	$ 0
Operating Loss Carryforwards Expiration Period	2031
Company's tax years beginning for examination	4 years

Net loss per share, basic and diluted - Calculation of basic and diluted net loss per share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Earnings Per Share [Abstract]
Net loss	$ (1,510)	$ (2,554)
Weighted average shares outstanding (in shares)	5,405,388	5,123,568
Basic and diluted loss per share (in dollars per share)	$ (0.28)	$ (0.50)

Net loss per share, basic and diluted - Summary of outstanding shares of common stock equivalents excluded from computation of diluted net loss per share (Details 1) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Weighted average shares outstanding:
Total	2,842,024	2,732,501
Common stock warrants
Weighted average shares outstanding:
Total	747,121	387,599
Options
Weighted average shares outstanding:
Total	2,094,903	2,044,902